# EDGAR Filing Document

**Accession Number:** 0001945557
**File Stem:** 0001945557-26-000002
**Filing Date:** 2026-2
**Character Count:** 8353
**Document Hash:** 16328428b19f1b319a453ea708656189
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001945557-26-000002.hdr.sgml**: 20260202

**ACCESSION NUMBER**: 0001945557-26-000002

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20260129

**FILED AS OF DATE**: 20260202

**DATE AS OF CHANGE**: 20260202

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Schafer Joshua
- **CENTRAL INDEX KEY:** 0001945557

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-36913
- **FILM NUMBER:** 26588955

**MAIL ADDRESS:**
- **STREET 1:** SHUTTLE PHARMACEUTICALS HOLDINGS, INC.
- **STREET 2:** ONE RESEARCH COURT, SUITE 450
- **CITY:** ROCKVILLE
- **STATE:** MD
- **ZIP:** 20850
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ZEVRA THERAPEUTICS, INC.
- **CENTRAL INDEX KEY:** 0001434647
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 205894398
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 1180 CELEBRATION BOULEVARD, SUITE 103
- **CITY:** CELEBRATION
- **STATE:** FL
- **ZIP:** 34747
- **BUSINESS PHONE:** (321) 939-3416

**MAIL ADDRESS:**
- **STREET 1:** 1180 CELEBRATION BOULEVARD, SUITE 103
- **CITY:** CELEBRATION
- **STATE:** FL
- **ZIP:** 34747

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** KEMPHARM, INC
- **DATE OF NAME CHANGE:** 20130530

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** KEMPHARM INC
- **DATE OF NAME CHANGE:** 20080507

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[x] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Schafer Joshua<br><sub>(Last) (First) (Middle)</sub><br>C/O ZEVRA THERAPEUTICS, INC.<br>1180 CELEBRATION BOULEVARD, SUITE 103<br><sub>(Street)</sub><br>CELEBRATION, FL 34747<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2026-01-29 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [ ] 10% Owner<br>[X] Officer (give title below) [ ] Other (specify below)<br>_CCO_ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>ZEVRA THERAPEUTICS, INC. [ ZVRA ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Common Stock | 2026-01-30 |  | M |  | 11333 | A | <sup>(1)</sup> | 40819 | D |  |
| Common Stock | 2026-01-30 |  | S<sup>(2)</sup> |  | 3375 | D | 8.8297<sup>(3)</sup> | 37444 | D |  |
| Common Stock | 2026-01-31 |  | M |  | 35334 | A | <sup>(1)</sup> | 72778 | D |  |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Restricted Stock Unit | <sup>(1)</sup> | 2026-01-29 |  | A |  | 37500 |  | <sup>(4)</sup> | <sup>(4)</sup> | Common Stock | 37500 | $0 | 37500 | D |  |
| Stock Option (right to buy) | $8.86 | 2026-01-29 |  | A |  | 75000 |  | <sup>(5)</sup> | 2036-01-28 | Common Stock | 75000 | $0 | 75000 | D |  |
| Restricted Stock Unit | <sup>(1)</sup> | 2026-01-30 |  | M |  |  | 11333 | <sup>(6)</sup> | <sup>(6)</sup> | Common Stock | 11333 | $0 | 22667 | D |  |
| Restricted Stock Unit | <sup>(1)</sup> | 2026-01-31 |  | M |  |  | 35334 | <sup>(7)</sup> | <sup>(7)</sup> | Common Stock | 35334 | $0 | 35333 | D |  |

---

### Footnotes:

(1) Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

(2) Adoption date of referenced 10b5-1(c) plan is: 3/27/2025.

(3) This transaction was executed in multiple trades at prices ranging from $8.64 to $9.03. The price reported reflects the weighted average sale price. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer or any security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.

(4) The restricted stock units will vest and settle as to one third of the restricted stock units on January 29, 2027, and the remaining two thirds of the restricted stock units will vest and settle in equal annual installments thereafter, subject in each case to the Reporting Person's continued service through such vesting date.

(5) Grant to the Reporting Person of a stock option under the Issuer's Amended and Restated 2014 Equity Incentive Plan. The option will vest and become exercisable in four equal annual installments beginning on the first anniversary of the grant date, subject to the Reporting Person's continued service on such vesting date.

(6) One third of the restricted stock units vested and settled on January 30, 2026. The remaining two thirds of the shares will vest and settle in equal annual installments thereafter, subject in each case tothe Reporting person's continued service through such vesting date.

(7) One third of the restricted stock units vested and settled on each of January 31, 2025 and January 31, 2026. The remaining one third of the shares will vest and settle on January 31, 2027, subject tothe Reporting person's continued service through such vesting date.

**Signature:** /s/ Timothy J. Sangiovanni, Attorney-in-Fact for Joshua Schafer  
**Date:** 2026-02-02

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**